New hope for tough prostate cancer: experimental combo targets resistant tumors
NCT ID NCT07389187
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug (LC-K76) combined with an immunotherapy (Tislelizumab) and hormone therapy in 10 men with metastatic castration-resistant prostate cancer that has worsened after standard treatments. The goal is to check safety and see if the combination can shrink tumors or slow the disease. Participants take oral and intravenous medications for 24 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MCRPC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Changzheng hospital
Shanghai, Shanghai Municipality, 201109, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Half the dose, same hope? trial tests cutting hormone therapy in prostate cancer
- Can a new daily pill slow advanced prostate cancer?
- New radioactive drug takes aim at Hard-to-Treat prostate cancer
- Promising prostate cancer drug gets extended trial for those already benefiting
- New antibody combo aims to control hard-to-treat prostate cancer
- Experimental cell therapy aims to boost immune system against Hard-to-Treat prostate cancer